Venetoclax duration (14 vs. 21 vs. 28 days) in combination with hypomethylating agent in newly diagnosed acute myeloid leukemia: Comparative analysis of response, toxicity, and survival

Overall survival and response rates of 270 patients with newly diagnosed acute myeloid leukemia receiving venetoclax (Ven) plus hypomethylating agent, stratified by Ven dosing schedule (Cycle 1 Ven 14 vs. 21 vs. 28 days).

Saved in:
Bibliographic Details
Published inAmerican journal of hematology Vol. 99; no. 2; pp. E63 - E66
Main Authors Karrar, Omer, Abdelmagid, Maymona, Rana, Masooma, Iftikhar, Moazah, McCullough, Kristen, Al‐Kali, Aref, Alkhateeb, Hassan B., Begna, Kebede H., Elliott, Michelle A., Mangaonkar, Abhishek, Saliba, Antoine, Hefazi Torghabeh, Mehrdad, Litzow, Mark R., Hogan, William, Shah, Mithun, Patnaik, Mrinal M., Pardanani, Animesh, Badar, Talha, Murthy, Hemant, Foran, James, Palmer, Jeanne, Sproat, Lisa, Khera, Nandita, Arana Yi, Cecilia, Tefferi, Ayalew, Gangat, Naseema
Format Journal Article
LanguageEnglish
Published Hoboken, USA John Wiley & Sons, Inc 01.02.2024
Wiley Subscription Services, Inc
Subjects
Acute myeloid leukemia
Comparative analysis
Hematology
Survival
Toxicity
Online AccessGet full text
ISSN0361-8609
1096-8652
1096-8652
DOI10.1002/ajh.27180

Cover

More Information
Summary:Overall survival and response rates of 270 patients with newly diagnosed acute myeloid leukemia receiving venetoclax (Ven) plus hypomethylating agent, stratified by Ven dosing schedule (Cycle 1 Ven 14 vs. 21 vs. 28 days).
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ObjectType-Correspondence-1
ISSN:0361-8609
1096-8652
1096-8652
DOI:10.1002/ajh.27180